News Headlines Article

FDA advisory group gives mixed review of Theravance pneumonia treatment
San Francisco Business Times

An advisory committee recommended Thursday that the Food and Drug Administration approve an antibiotic for hospital-acquired pneumonia developed by Theravance Inc. when there are no other alternatives, potentially giving doctors another weapon to treat the superbug MRSA. But the Anti-Infective Drugs Advisory Committee did not recommend the once-a-day injectable drug, called Vibativ, as a first-line treatment for nosocomial pneumonia.

Commands